-
Innovation Ranking
NewInnovation Ranking – Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, is focused on the research, development, manufacturing, commercialization, import and export of biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of various therapeutic areas including, cancer; bone and joint diseases; renal diseases; immune disorders and infectious diseases and others. It also offers drugs to aid the kidney, liver and other organ transplants. It also has a range of product candidates in its pipeline. Operating through its...
-
Product Insights
NewNet Present Value Model: Chugai Pharmaceutical Co Ltd’s AMY-109
Empower your strategies with our Net Present Value Model: Chugai Pharmaceutical Co Ltd's AMY-109 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of Chugai Pharmaceutical Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Chugai Pharmaceutical Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ROSE-12 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ROSE-12 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ROSE-12 in Solid Tumor Drug Details: ROSE12 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SPYK-04 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SPYK-04 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SPYK-04 in Non-Small Cell Lung Cancer Drug Details: SPYK-04 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMY-109 in Endometriosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMY-109 in Endometriosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMY-109 in Endometriosis Drug Details: AMY-109 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAIL-66 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAIL-66 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAIL-66 in Solid Tumor Drug Details: SAIL-66 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ITIL-306 in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ITIL-306 in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ITIL-306 in Lung Adenocarcinoma Drug Details: ITIL-306 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dresbuxelimab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dresbuxelimab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dresbuxelimab in Pancreatic Ductal Adenocarcinoma Drug Details: Dresbuxelimab (AK-119) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SGN-1 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SGN-1 in Ovarian Cancer Drug Details: SGN-1 is under development for...